相关实验视频
Updated: Jul 18, 2026
04:48
Control of Eating Behavior Using a Novel Feedback System
Published on: May 8, 2018
体重控制和降低肥胖患者的危险因素治疗2年与orlistat:一个随机对照试验
M H Davidson1, J Hauptman, M DiGirolamo
1Chicago Center for Clinical Research, Ill, USA.
JAMA
|January 26, 1999
概括
体重减轻药物奥利斯塔特 (Orlistat) 与饮食相结合,在两年内显著降低了体重并改善了相关健康因素. 这种肥胖治疗也帮助患者比安慰剂更有效地维持体重减轻.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肥胖问题研究研究
- 心血管健康 心血管健康
背景情况:
- 奥尔利斯塔特是一种胃肠道脂酶抑制剂,可降低饮食脂肪的吸收.
- 它是减肥和降低心血管风险的潜在帮助.
研究的目的:
- 评估orlistat与饮食干预相结合的两年内减肥和维持体重的疗效.
- 为了比较orlistat加饮食与安慰剂加饮食.
主要方法:
- 这是一项随机,双盲,安慰剂控制的研究,涉及18个美国研究中心的肥胖成年人 (BMI 30-43 kg/m2).
- 参与者接受了可控能量饮食,并随机分配给orlistat (120毫克每天3次) 或安慰剂52周,随后进行体重维持阶段,再调整orlistat或安慰剂剂量52周.
- 主要结局措施包括体重变化和血压,血清脂质,葡萄糖和胰岛素水平的变化.
主要成果:
- 与安慰剂相比,奥利斯塔特治疗在第一年导致体重减轻显著增加 (8.76公斤对比5.81公斤).
- 在两年内,120毫克的orlistat组的体重恢复 (35.2%) 与60毫克的orlistat组 (51.3%) 和安慰剂组 (63.4%) 相比较少.
- 使用120毫克奥利斯塔特的治疗与禁食低密度脂蛋白胆固醇和胰岛素水平的改善有关.
结论:
- 与饮食结合使用orlistat治疗两年的时间显著促进了减肥.
- 奥利斯塔特治疗有助于减轻重量恢复,并改善某些与肥胖相关的疾病风险因素.
- 结合orlistat和饮食干预,为长期的体重管理提供了一个可行的策略.
相关概念视频
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...